Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy

• Main Authors: Ling L., Tan S.K., Goh T.H., Cheung E., VICTOR NURCOMBE, van Wijnen A.J., Cool S.M.
• Other Authors: BIOCHEMISTRY
• Format: Article
• Published: BioMed Central Ltd. 2020
• Subjects: 1 tert butyl 3 [6 (3,5 dimethoxyphenyl) 2 (4 diethylaminobutylamino)pyrido[2,3 d]pyrimidin 7 yl]urea; 3 [4 methyl 2 (2 oxo 3 indolinylmethylidenyl) 3 pyrrolyl]propionic acid; antibodies,antisera and immunoglobulins; antineoplastic agent; fibroblast growth factor receptor 1; heparan sulfate; heparin binding protein; imb r1; phospholipase C gamma; protein p53; unclassified drug; fibroblast growth factor 2; heparin; messenger RNA; monoclonal antibody; antioxidant assay; apoptosis; Article; cancer survival; cell survival; controlled study; cross reaction; down regulation; drug protein binding; enzyme activation; enzyme linked immunosorbent assay; human; human cell; immunohistochemistry; methodology; proof of concept study; protein domain; protein targeting; quantitative analysis; real time polymerase chain reaction; sequence homology; signal transduction; Student t test; upregulation; Western blotting; antagonists and inhibitors; biopsy; cell proliferation; chemistry; drug effects; gene expression regulation; genetics; metabolism; molecularly targeted therapy; Neoplasms; pathology; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Biopsy; Cell Proliferation; Fibroblast Growth Factor 2; Gene Expression Regulation, Neoplastic; Heparin; Humans; Molecular Targeted Therapy; Protein Interaction Domains and Motifs; Receptor, Fibroblast Growth Factor, Type 1; RNA, Messenger; Signal Transduction
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/174283
• Institution: National University of Singapore

10.1186/s12943-015-0391-4